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Background: Oxygen saturation has been shown in risk score models to predict mortality in emergency medicine.
The aim of this study was to determine whether low oxygen saturation measured by a single-point measurement
by pulse oximetry (SpO2) is associated with increased mortality in the general adult population.
Methods: Pulse oximetry was performed in 5,152 participants in a cross-sectional survey in Tromsø, Norway, in
2001–2002 (“Tromsø 5”). Ten-year follow-up data for all-cause mortality and cause of death were obtained from the
National Population and the Cause of Death Registries, respectively. Cause of death was grouped into four categories:
cardiovascular disease, cancer except lung cancer, pulmonary disease, and others. SpO2 categories were assessed as
predictors for all-cause mortality and death using Cox proportional-hazards regression models after correcting for age,
sex, smoking history, body mass index (BMI), C-reactive protein level, self-reported diseases, respiratory symptoms, and
spirometry results.
Results: The mean age was 65.8 years, and 56% were women. During the follow-up, 1,046 (20.3%) participants died.
The age- and sex-adjusted hazard ratios (HRs) (95% confidence intervals) for all-cause mortality were 1.99 (1.33–2.96)
for SpO2≤ 92% and 1.36 (1.15–1.60) for SpO2 93–95%, compared with SpO2≥ 96%. In the multivariable Cox
proportional-hazards regression models that included self-reported diseases, respiratory symptoms, smoking
history, BMI, and CRP levels as the explanatory variables, SpO2 remained a significant predictor of all-cause
mortality. However, after including forced expiratory volume in 1 s percent predicted (FEV1% predicted), this
association was no longer significant. Mortality caused by pulmonary diseases was significantly associated with
SpO2 even when FEV1% predicted was included in the model.
Conclusions: Low oxygen saturation was independently associated with increased all-cause mortality and
mortality caused by pulmonary diseases. When FEV1% predicted was included in the analysis, the strength of
the association weakened but was still statistically significant for mortality caused by pulmonary diseases.Background
Pulse oximeters are cheap and are used widely as non-
invasive devices for estimating oxygen saturation (SpO2).
Pulse oximetry is used extensively in clinical medicine to
evaluate and monitor patients. Low oxygen saturation or
hypoxemia is associated with conditions or diseases in-
volving ventilation–perfusion mismatch in the lungs,
hypoventilation, right-to-left shunts, reduced diffusion
capacity, and reduced oxygen partial pressure in inspired* Correspondence: monica.linea.vold@unn.no
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unless otherwise stated.air. There is no clear cut-off point for abnormal oxygen
saturation, but SpO2 ≤ 95% is used in most adult studies.
In materials for blood gas reference values, Crapo et al.
reported a mean arterial oxygen saturation (SaO2) of
95.5–96.9% (standard deviation (SD) 0.4–1.4) [1]. In a
more recent paper, the median SaO2 was 98.2% (range
96.6–99.5%) in the 20–39-year-old age group and 98.0%
(range 95.1–99.7%) in the 40–76-year-old age group [2].
SaO2 decreased marginally with age by about 0.20% per
decade. A resting SpO2 ≤ 95% has been found to predict
oxygen desaturation during sleep, exercise, and air plane
travel in chronic obstructive pulmonary disease (COPD)
patients [3-5]. SpO2 ≤ 95% has also been identified as a
risk factor for postoperative pulmonary complications
[6]. The value of 96% seems a reasonable cut-off value.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for respiratory failure in COPD patients [7]. In emergency
medicine, low SpO2 has been shown to be associated with
increased mortality [8,9] and is included together with
other vital signs when calculating the risk score for pre-
dicting prognosis [10-13]. Different risk-scoring models to
predict mortality use different limits from <90 to ≤95%
[10-14]. In lung diseases such as COPD, the partial pres-
sure of oxygen (PaO2) is used most often in models to
predict mortality [15]. Higher oxygen saturation has been
shown in survivors [16,17], but neither SpO2 nor PaO2
was found to be a significant predictor when added to a
validated multi-dimensional disease rating that included
the body mass index (B), degree of airflow obstruction
(O), dyspnoea (D), and exercise capacity (E) (BODE Index)
in multivariable analysis [15].
There is limited information about low oxygen satur-
ation and its association with mortality in the general
population. In a previous study, we found that the most
important predictors for low oxygen saturation in an adult
population were increased body mass index (BMI)
and reduced lung function, which was defined as de-
creased forced expiratory volume in 1 s percent pre-
dicted (FEV1% predicted) [18]. We also found that
smoking history, dyspnoea, elevated haemoglobin con-
centration, age, and male sex predicted low oxygen satur-
ation. FEV1% predicted is a predictor of mortality in both
surveys of the general population [19] and COPD studies
[15]. Low BMI has been associated with increased mortal-
ity both in epidemiological surveys [20,21] and COPD
studies [22,23].
It is known that older age, male sex, smoking history
(both current and former smoker), pack years (former
smoker is often not significant when pack years are in-
cluded) [19], and a history of cardiovascular disease (CVD),
hypertension, or diabetes predict mortality in studies of
the general adult population [24]. Biomarkers such as in-
creased C-reactive protein (CRP) concentration have been
found to predict mortality in both the general population
[25] and patients with COPD [26].
The aim of this study was to examine whether a single-
point measurement of a low SpO2 is associated with all-
cause mortality and cause of death, especially death due to
pulmonary diseases, in the general adult population after
correcting for other established risk factors.
Methods
Subjects
The Tromsø Study comprises repeated cross-sectional
population-based surveys, which were initiated in 1974
[27]. Tromsø is a university city in northern Norway
where the population recently exceeded 70,000. Tromsø
is situated at sea-level, and the oxygen partial pressure
in inspired air is not reduced. The fifth Tromsø Studysurvey was performed in 2001–2002 and was conducted
by the Department of Community Medicine, University
of Tromsø, in co-operation with the National Health
Screening Service. In the fourth survey, all inhabitants
aged 55–74 years and 5–10% of the samples in the other
age groups between 25 and 84 years were asked to take
part in a second, more-extensive medical examination
(77% agreed to participate). All participants from this sec-
ond visit were invited to participate in the Tromsø 5 sur-
vey and were eligible for a second visit. In Tromsø 5, the
first visit was attended by 8,130 subjects, which was 79%
of those invited. At the second visit, 5,905 attended (84%),
and SpO2 was measured by pulse oximetry in 5,152 partic-
ipants (Figure 1). Lack of staff was the main reason why
pulse oximetry and spirometry were not performed in
13% of the participants.
Examinations
A questionnaire was mailed together with an invitation
to participate in the study. The questionnaire included
questions about the participant’s history of diseases, re-
spiratory symptoms, and smoking habits. Participants
who reported experiencing angina pectoris, myocardial
infarction, or cerebral stroke were classified as having
“self-reported CVD”. Participants who used antihyperten-
sive drugs were classified as having “self-reported hyper-
tension”. The examinations at the first visit included height
and weight, and BMI (kg/m2) was calculated.
Pulse oximetry and spirometry were measured during
the second visit. SpO2 values were measured with a digital
handheld pulse oximeter (Onyx II, model 9550, Nonin
Medical, Inc., Plymouth, MN, USA). The participants
rested at least 15 minutes before the measurement. The
highest of three measurements was recorded. The manu-
facturer’s testing has shown that only values between
70% and 100% are accurate to within ±2 digits, and values
<70% were regarded as invalid.
Spirometry was performed using the Vmax Legacy 20
system (VIASYS Healthcare Respiratory Technologies,
Yorba Linda, CA, USA). American Thoracic Society cri-
teria [28] were followed. Norwegian reference values for
pre-bronchodilatory spirometry [29] were used because
reversibility testing was not performed. Calibration of the
instrument was performed every morning and as the ma-
chine required. Three trained technicians conducted the
spirometry. Current drug therapy was not interrupted be-
fore the test. Both pulse oximetry and spirometry were re-
corded in 5,131 individuals, and a valid FEV1% predicted
was obtained in 4,988 of these participants.
On the same day, as part of the second examination,
blood was drawn for measurement of the concentrations
of haemoglobin [30] and CRP. CRP concentration was
measured using a high-sensitivity immunoturbidimetric
assay [31].
26,956 attended first visit T4 
10,542 eligible for second visit T4 
7,916 attended second visit T4 
7,022 eligible for second visit T5
533 died
361 moved/emigrated
5,905 attended second visit T5 
5,152 examined by pulse oximetry 
753 not examined by pulse oximetry 
2,626 did not attend second visit T4 
1,117 did not attend second visit T5
Figure 1 Flow chart of participants from Tromsø 4 (T4) to Tromsø 5 (T5).
Figure 2 Causes of death for the 1,046 deaths.
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Ten-year follow-up data for all-cause mortality were ob-
tained from the National Population Register of Norway
and causes of death from the National Cause of Death
Registry. Subjects who emigrated were censored at the
date of emigration. If subjects had not died or emigrated,
they were censored at 10 years from the baseline. The
causes of death were classified into four categories: CVD,
cancer except lung cancer, pulmonary disease (including
COPD, asthma, interstitial lung diseases, sequelae of tu-
berculosis, and lung cancer), and others. Continuous vari-
ables were categorized. We defined a low pulse oximetry
value as an SpO2 ≤ 95%. SpO2 values were categorized into
three groups: reduced, ≤92%; mildly reduced, 93–95%;
and normal, ≥96%. Characteristics of the participants were
categorized according to SpO2 and mortality status, and
differences were assessed using the chi-square test.
Associations with all-cause mortality and mortality caused
by pulmonary diseases were analysed by Cox proportional-
hazards regression for SpO2, smoking history, self-reported
respiratory symptoms and diseases, BMI, CRP concentra-
tion, and spirometry measures, and were adjusted for age
and sex. The significant predictors of mortality at the 5%level were entered into multivariable Cox proportional-
hazards regression models. Knowing that FEV1% predicted
is associated with both SpO2 and mortality, models with
and without FEV1% predicted included were applied. IBM
SPSS statistical software version 20 (IBM, Armonk, NY,
USA) was used.
The Regional Committee for Medical and Health Research
Ethics in North Norway approved the Tromsø 5 survey.
All participants gave written informed consent.
Table 1 Baseline characteristics classified by arterial oxygen saturation (SpO2) in 5,152 participants
≤92% 93–95% ≥96% p-value
n (%) n (%) n (%)
All 53 (1.0) 537 (10.4) 4,562 (88.5)
Sex 0.47
Female 34 (1.2) 297 (10.3) 2,556 (88.5)
Male 19 (0.8) 240 (10.6) 2,006 (88.6)
Age (years) <0.001*
<60 1 (0.1) 57 (5.3) 1,027 (94.7)
60–70 16 (0.7) 217 (10.2) 1,902 (89.1)
≥70 36 (1.9) 263 (13.6) 1,633 (84.5)
Self-reported diseases
CVD <0.001
No 39 (0.9) 410 (9.6) 3,814 (89.5)
Yes 14 (1.6) 127 (14.3) 748 (84.1)
Asthma <0.001
No 37 (0.8) 448 (9.6) 4,197 (89.6)
Yes 16 (3.4) 89 (18.9) 365 (77.7)
COPD <0.001
No 39 (0.8) 476 (9.8) 4,366 (89.4)
Yes 14 (5.2) 61 (22.5) 196 (72.3)
Diabetes 0.004
No 49 (1.0) 499 (10.1) 4,373 (88.9)
Yes 4 (1.7) 38 (16.5) 189 (81.8)
Hypertension 0.020
No 40 (1.0) 378 (9.7) 3,463 (89.2)
Yes 13 (1.0) 159 (12.5) 1099 (86.5)
Smoking history 0.001*
Never 16 (0.9) 141 (8.1) 1,581 (91.0)
Former 21 (1.0) 241 (11.6) 1,819 (87.4)
Current 16 (1.2) 155 (11.6) 1,162 (87.2)
Self-reported symptoms
Dyspnoea# <0.001*
0 17 (0.6) 221 (8.0) 2,511 (91.3)
1 17 (0.8) 244 (11.9) 1,785 (87.2)
≥2 19 (5.3) 72 (20.2) 266 (74.5)
Chronic cough with sputum <0.001
No 44 (0.9) 460 (9.7) 4,261 (89.4)
Yes 9 (2.3) 77 (19.9) 301 (77.8)
BMI (kg/m2) <0.001*
<18.5 1 (2.0) 6 (12.2) 42 (85.7)
18.5-24.9 16 (1.0) 107 (6.4) 1,548 (92.6)
25.0-29.9 21 (0.9) 239 (10.2) 2,082 (88.9)
≥30.0 15 (1.4) 180 (17.0) 865 (81.6)
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Table 1 Baseline characteristics classified by arterial oxygen saturation (SpO2) in 5,152 participants (Continued)
CRP (mg/L) <0.001
<5 36 (0.8) 421 (9.7) 3,871 (89.4)
≥5 17 (2.3) 109 (14.7) 615 (83.0)
Haemoglobin§ 0.29
≤upper limit 48 (1.0) 469 (10.3) 4,052 (88.7)
>upper limit 0 (0.0) 4 (21.1) 15 (78.9)
FEV1% predicted <0.001
*
<50 16 (8.2) 66 (34.0) 112 (57.7)
50–80 22 (1.3) 223 (13.3) 1,427 (85.3)
≥80 13 (0.4) 227 (7.3) 2,882 (92.3)
FEV1/FVC% <0.001
<0.7 26 (2.4) 185 (16.8) 890 (80.8)
≥0.7 25 (0.6) 335 (8.6) 3,551 (90.8)
*Chi-square trend.
#Dyspnoea: 0, no dyspnoea; 1, dyspnoea walking rapidly on level ground or up a moderate slope; ≥2, dyspnoea walking slowly on level ground, washing or
dressing, or at rest.
§Upper limits: women, 16.0 g/dL; men, 17.0 g/dL.
Definitions of abbreviations: SpO2, arterial oxygen saturation as measured by pulse oximetry; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary
disease; BMI, body mass index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Vold et al. BMC Pulmonary Medicine  (2015) 15:9 Page 5 of 12Results
SpO2 values were recorded for 5,152 people in Tromsø 5.
Their mean age was 65.8 years (SD 9.5; range 32–89 years),
and 2,887 (56%) were women. During the follow-up period
from 2001–2002 until 2011–2012, 1,046 (20.3%) died: 346
(33.1%) died of CVD, 299 (28.6%) of cancer except lung
cancer, 161 (15.4%) of pulmonary disease, and 240 (22.9%)
of other diseases (Figure 2). The mean follow-up period
was 9.2 years (SD 2.0). An SpO2 ≤ 95% was found in 11.5%
of the population.
Table 1 shows the baseline characteristics grouped ac-
cording to SpO2. Low SpO2 was significantly associated
with older age, self-reported diseases and symptoms,
smoking history, high BMI and CRP concentration, and low
FEV1% predicted and FEV1/forced vital capacity (FVC)%.
A high haemoglobin concentration was not significantly
associated with low SpO2 and was not included in further
analysis.
Table 2 shows the characteristics according to mortal-
ity status. The group of participants who had died were
more likely to have been older and male; to have smoked
more; and to have had more self-reported diseases and
respiratory symptoms, a lower BMI, FEV1% predicted,
FEV1/FVC%, and SpO2, and a higher CRP concentration.
The frequency of death due to pulmonary diseases in-
creased by decreasing SpO2: 104 out of 4563 (2.3%) par-
ticipants with baseline SpO2 > 96%, 45 out of 537 (8.4%)
with SpO2 93-95%, and 12 out of 53(22.6%) with SpO2 ≤
92%, p < 0.001.
Figure 3 shows the Kaplan–Meier survival curve for
the different levels of SpO2. After adjusting for age and
sex in the Cox proportional-hazards regression, thefollowing factors were significantly associated with all-
cause mortality and mortality caused by pulmonary dis-
eases: lower SpO2, FEV1% predicted, FEV1/FVC%, and
BMI; higher CRP concentration; smoking history; and
self-reported diseases and respiratory symptoms (Table 3).
The highest HRs for all-cause mortality were found for
FEV1% predicted <50, current smoking, history of dia-
betes, and SpO2 ≤ 92% (3.07, 2.11, 2.08, and 1.99, respect-
ively). For pulmonary diseases, the highest HRs were
found for FEV1% predicted <50, current smoking, and
SpO2 ≤ 92% (16.35, 14.21, and 9.12, respectively) (Table 4).
A multivariable Cox proportional-hazards regression
model for all-cause mortality that included all the vari-
ables except spirometry values produced HRs of 1.73
(95% confidence interval (CI) 1.15–2.60) and 1.27 (95% CI
1.06–1.51) for an SpO2 ≤ 92% and 93–95%, respectively.
However, adding FEV1% predicted as an explanatory vari-
able in the model decreased the HRs of SpO2 significantly,
and although the association indicated a trend, it was not
significant (Table 3).
Using the same models with mortality caused by pul-
monary diseases as the outcome (Table 4), SpO2 was a
significant variable, even when FEV1% predicted was in-
cluded. The HRs for SpO2 ≤ 92% and 93–95% were 3.17
(95% CI 1.53–6.56) and 1.97 (95% CI 1.33–2.92), re-
spectively. Examining the HR of low SpO2 for any other
cause of death showed no significant associations except
for heart failure (20 deaths), which occurred in a subgroup
of those who had died from CVD. The HRs for death
caused by heart failure was also significantly increased
when FEV1% predicted was included in the model. FEV1%
predicted was significantly associated with mortality
Table 2 Baseline characteristics classified by 10-year
mortality status in 5,152 participants
Total (n) Dead (n) % p-value
All 5,152 1,046 (20.3)
Sex <0.001
Female 2,887 459 (15.9)
Male 2,265 587 (25.9)
Age (years) <0.001*
<60 1,085 43 (4.0)
60-70 2,135 274 (12.8)
≥70 1,932 729 (37.7)
Self-reported diseases
CVD <0.001
No 4,263 742 (17.4)
Yes 889 304 (34.2)
Asthma <0.001
No 4,682 914 (19.5)
Yes 470 132 (28.1)
COPD <0.001
No 4,881 950 (19.5)
Yes 271 96 (35.4)
Diabetes <0.001
No 4,921 959 (19.5)
Yes 231 87 (37.7)
Hypertension <0.001
No 3,881 697 (18.0)
Yes 1271 349 (27.5)
Smoking history <0.001*
Never 1,736 269 (15.5)
Former 2,083 464 (22.3)
Current 1,333 313 (23.5)
Self-reported symptoms
Dyspnoea# <0.001*
0 2,749 486 (17.7)
1 2,046 437 (21.4)
≥2 357 123 (34.5)
Chronic cough with sputum
No 4,765 920 (19.3) <0.001
Yes 387 126 (32.6)
BMI (kg/m2) <0.001*
<18.5 49 22 (44.9)
18.5-24.9 1,671 367 (22.0)
25.0-29.9 2,342 451 (19.3)
≥30.0 1,060 193 (18.2)
Table 2 Baseline characteristics classified by 10-year
mortality status in 5,152 participants (Continued)
CRP (mg/L) <0.001
<5 4,328 808 (18.7)
≥5 741 213 (28.7)
FEV1% predicted <0.001
*
<50 194 99 (51.0)
50–80 1,672 434 (26.0)
≥80 3,122 456 (14.6)
FEV1/FVC% <0.001
<70 1,101 386 (35.1)
≥70 3,911 612 (15.6)
SpO2 (%) <0.001
*
≤92 53 25 (47.2)
93–95 537 163 (30.4)
≥96 4,562 858 (18.8)
*Chi-square trend.
#Dyspnoea: 0, no dyspnoea; 1, dyspnoea walking rapidly on level ground or up
a moderate slope; ≥2, dyspnoea walking slowly on level ground, washing or
dressing, or at rest.
Definitions of abbreviations: CVD, cardiovascular disease; COPD, chronic
obstructive pulmonary disease; BMI, body mass index; CRP, C-reactive protein;
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SpO2, arterial
oxygen saturation as measured by pulse oximetry.
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ary diseases but not with other diseases.
FEV1/FVC% was not significantly associated with all-
cause mortality when included as a dichotomous variable
(threshold of <0.7) or as a continuous variable in the
multivariable model that included FEV1% predicted.
FEV1/FVC% was a significant independent predictor of
death caused by pulmonary diseases.
Cox proportional-hazards regression was also performed
with the independent variables as continuous variables ex-
cluded by backward stepwise elimination. Only predictors
with p < 0.05 were kept in the final model. With all the
variables in the model, the HR per % SpO2 was 0.96 (95%
CI 0.92–1.00; p = 0.026) and the HR per % FEV1% pre-
dicted was 0.99 (95% CI 0.98–0.99; p < 0.001).
Discussion
In this study, we found that low oxygen saturation, defined
as SpO2 ≤ 95% measured by a single-point measurement
with pulse oximetry, was associated with increased all-
cause mortality and mortality caused by pulmonary dis-
eases. This has not been described previously in population
studies. This association remained significant after adjust-
ing for sex, age, history of smoking, self-reported diseases
and respiratory symptoms, BMI, and CRP concentration.
When including FEV1% predicted as a covariate, the HR
for low SpO2 remained significant for pulmonary diseases
but was no longer significant for all-cause mortality. The
Figure 3 Kaplan–Meier survival curves for different levels of oxygen saturation (SpO2).
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respiratory failure seem to be predicted by low SpO2 in
addition to spirometry in the general population.
There are probably several explanations as to why oxy-
gen saturation is associated with mortality. Low SpO2 is
a marker of cardiopulmonary diseases, which are among
the leading causes of death in this population. Thirty-
three per cent of deaths were caused by CVD, and 14%
of deaths were caused by lung cancer and COPD. CVD
predisposes a person to heart failure, which may affect pul-
monary function and cause low SpO2. Even though SpO2
was not a significant predictor of death caused by CVD, we
found a significant association with death caused by heart
failure even when spirometry was included in the multivari-
able analysis. It is not surprising that low lung function, as
measured by SpO2 and spirometry, is associated with death
caused by pulmonary diseases. Lung cancer is associated
with other respiratory diseases [32]. Severe respiratory dis-
ease in people with lung cancer limits the treatment modal-
ities, among other surgery, and hence lower survival [33].
SpO2 has been shown to be a predictor of survival in lung
cancer [34]. Spirometry has limitations in assessing the se-
verity of pulmonary diseases, especially in the presence of
reduced diffusion capacity as occurs in emphysema and
interstitial lung disease. Therefore, SpO2 may be an inde-
pendent risk factor when the results of other lung function
tests, such as the 6 min walk test or diffusing capacity/
transfer factor of the lung for carbon monoxide, are not
available.Comparison with previous studies
In a recently published study [18], we reported a preva-
lence of 6.3% for SpO2 ≤ 95% in Tromsø 6, which was
lower than the 11.5% found in this study from Tromsø
5. The main reason for this difference is probably that a
higher percentage was smokers in Tromsø 5 than in
Tromsø 6 (25.9% and 18.0%, respectively). There was
also a higher mean age in Tromsø 5: 65.8 years (SD 9.5)
compared with 63.6 (SD 9.2) in Tromsø 6. The most
important predictors of low SpO2 in Tromsø 6, BMI
and FEV1% predicted, were significantly associated
with mortality in a multivariable model in the present
study. However, survival was not significantly lower
for people with a higher BMI even though a higher BMI
level was associated with low SpO2. Obesity is associated
with sleep apnoea [35], obesity hypoventilation [36], dia-
betes, hypertension, and CVD [37]. Sleep apnoea is as-
sociated with lower daytime PaO2 even in people with
normal spirometry values [38]. After correcting for these
factors, obesity itself is not associated with higher mor-
tality. In fact, for all-cause mortality it seems to have
a protective effect. Although overweight and obesity may
lead to decreased oxygen saturation, the risk of premature
death seems not to be increased as long as the lung func-
tion is normal and other comorbidities are adjusted
for. When including other comorbidities such as CVD,
hypertension, and diabetes, other studies have found
that obesity, when not very severe, does not increase
mortality [39-41].
Table 3 Hazard ratios for 10-year all-cause mortality in 3 different models*
Model 1 Model 2 Model 3
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.13 (1.12–1.14) <0.001 1.12 (1.11–1.14) <0.001
Sex
Female 1 (reference) 1 (reference)
Male 1.70 (1.49–1.95) <0.001 1.66 (1.44–1.91) <0.001
Self-reported diseases
CVD 1.34 (1.17–1.54) <0.001 1.18 (1.01–1.37) 0.033 1.18 (1.01–1.37) 0.035
Asthma 1.33 (1.10–1.59) 0.003 1.03 (0.84–1.25) 0.81 0.92 (0.74–1.13) 0.41
COPD 1.75 (1.42–2.16) <0.001 1.29 (1.02–1.64) 0.036 1.13 (0.88–1.44) 0.35
Diabetes 2.08 (1.67–2.59) <0.001 2.09 (1.66–2.63) <0.001 1.88 (1.48–2.40) <0.001
Hypertension 1.20 (1.05–1.36) 0.006 1.24 (1.08–1.43) 0.003 1.24 (1.07–1.43) 0.004
Smoking history
Never 1 (reference) 1 (reference) 1 (reference)
Former 1.29 (1.10–1.52) 0.002 1.24 (1.05–1.46) 0.010 1.16 (0.98–1.38) 0.082
Current 2.11 (1.78–2.49) <0.001 1.89 (1.58–2.26) <0.001 1.68 (1.39–2.03) <0.001
Self-reported symptoms
Dyspnoea€
0 1 (reference) 1 (reference) 1 (reference)
1 1.19 (1.05–1.36) 0.007 1.06 (0.92–1.22) 0.42 1.02 (0.89–1.18) 0.76
≥2 1.71 (1.40–2.08) <0.001 1.32 (1.06–1.64) 0.015 1.15 (0.92–1.46) 0.23
Chronic cough with sputum
Yes 1.71 (1.42–2.07) <0.001 1.28 (1.04–1.57) 0.018 1.25 (1.01–1.54) 0.042
BMI (kg/m2)
<18.5 2.08 (1.35–3.20) 0.001 1.99 (1.27–3.11) 0.003 1.76 (1.08–2.84) 0.022
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25.0–29.9 0.85 (0.74–0.97) 0.018 0.82 (0.71–0.95) 0.008 0.84 (0.73–0.98) 0.024
≥30.0 0.80 (0.68–0.96) 0.015 0.68 (0.56–0.82) <0.001 0.71 (0.58–0.87) 0.001
CRP (mg/L)
<5 1 (reference) 1 (reference) 1 (reference)
≥5 1.57 (1.35–1.82) <0.001 1.39 (1.19–1.63) <0.001 1.36 (1.16–1.60) <0.001
FEV1% predicted
<50 3.07 (2.46–3.81) <0.001 1.99 (1.51–2.61) <0.001
50–80 1.54 (1.35–1.76) <0.001 1.29 (1.11–1.49) 0.001
≥80 1 (reference) 1 (reference)
FEV1/FVC%
<0.7 1.69 (1.49–1.93) <0.001 1.11 (0.95–1.31) 0.20
≥0.7 1 (reference) 1 (reference)
SpO2 (%)
≤92 1.99 (1.33–2.96) 0.001 1.73 (1.15–2.60) 0.008 1.42 (0.92–2.18) 0.11
93–95 1.36 (1.15–1.60) <0.001 1.27 (1.06–1.51) 0.009 1.13 (0.94–1.36) 0.19
≥96 1 (reference) 1 (reference) 1 (reference)
*Adjusted for age and sex in Model 1 and for all listed variables in the other two models.
€Dyspnoea: 0, no dyspnoea, 1, dyspnoea while walking rapidly on level ground or up a moderate slope, ≥2, dyspnoea while walking slowly on level ground,
washing or dressing, or at rest.
Definition of abbreviations: HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; BMI, body mass
index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SpO2, arterial oxygen saturation as measured by pulse oximetry.
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Table 4 Hazard ratios for 10-year mortality due to pulmonary diseases* in 3 different models€
Model 1 Model 2 Model 3
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.10 (1.07–1.12) <0.001 1.08 (1.05–1.11) <0.001
Sex
Female 1 (reference) 1 (reference)
Male 2.12 (1.50–2.98) <0.001 1.95 (1.37–2.79) <0.001
Self-reported diseases
CVD 1.16 (0.81–1.67) 0.42 1.21 (0.81–1.80) 0.36 1.28 (0.85–1.93) 0.23
Asthma 3.64 (2.57–5.16) <0.001 1.96 (1.32–2.92) 0.001 1.53 (1.02–2.31) 0.042
COPD 5.18 (3.57–7.52) <0.001 1.72 (1.10–2.69) 0.017 1.31 (0.83–2.06) 0.26
Diabetes 1.73 (0.94–3.19) 0.081 1.91 (1.01–3.64) 0.048 1.50 (0.76–2.98) 0.24
Hypertension 0.65 (0.44–0.95) 0.027 0.75 (0.49–1.14) 0.18 0.74 (0.48–1.12) 0.15
Smoking history
Never 1 (reference) 1 (reference) 1 (reference)
Former 4.74 (2.41–9.34) <0.001 3.78 (1.91–7.48) <0.001 3.08 (1.55–6.12) 0.001
Current 14.21 (7.32–27.59) <0.001 9.26 (4.69–18.28) <0.001 6.35 (3.17–12.71) <0.001
Self-reported symptoms
Dyspnoea#
0 1 (reference) 1 (reference) 1 (reference)
1 1.64 (1.17–2.31) 0.005 1.09 (0.75–1.58) 0.65 0.99 (0.67–1.45) 0.94
≥2 3.39 (2.16–5.33) <0.001 1.31 (0.77–2.24) 0.31 1.12 (0.64–1.94) 0.70
Chronic cough with sputum
Yes 1.85 (1.24–2.77) 0.003 1.86 (1.25–2.79) 0.002 1.63 (1.07–2.48) 0.022
BMI (kg/m2)
<18.5 2.92 (1.17–7.30) 0.022 1.75 (0.63–4.88) 0.29 0.83 (0.20–3.46) 0.80
18.5-24.9 1 (reference) 1 (reference) 1 (reference)
25.0-29.9 0.62 (0.44–0.88) 0.007 0.67 (0.47–0.96) 0.031 0.73 (0.50–1.06) 0.09
≥30.0 0.66 (0.42–1.03) 0.064 0.67 (0.41–1.08) 0.099 0.79 (0.49–1.30) 0.36
CRP (mg/L)
<5 1 (reference) 1 (reference) 1 (reference)
≥5 1.90 (1.32–2.74) 0.001 1.13 (0.77–1.68) 0.53 1.06 (0.71–1.58) 0.78
FEV1% predicted
<50 16.35 (10.51–25.43) <0.001 3.74 (2.07–6.77) <0.001
50–80 3.11 (2.10–4.60) <0.001 1.73 (1.11–2.68) 0.015
≥80 1 (reference) 1 (reference)
FEV1/FVC%
<0.7 5.18 (3.70–7.25) <0.001 1.64 (1.08–2.51) 0.022
≥0.7 1 (reference) 1 (reference)
SpO2 (%)
≤92 9.12 (4.99–16.67) <0.001 5.19 (2.70–9.99) <0.001 3.17 (1.53–6.56) 0.002
93–95 3.32 (2.33–4.71) <0.001 2.54 (1.75–3.68) <0.001 1.97 (1.33–2.92) 0.001
≥96 1 (reference) 1 (reference) 1 (reference)
*Pulmonary diseases: including COPD, asthma, interstitial lung disease, sequelae of tuberculosis, lung cancer.
€Adjusted for age and sex in Model 1 and for all listed variables in the other two models.
#Dyspnoea: 0, no dyspnoea; 1, dyspnoea while walking rapidly on level ground or up a moderate slope, ≥2, dyspnoea walking slowly on level ground, washing or
dressing, or at rest.
Definition of abbreviations: HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; BMI, body mass
index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SpO2, arterial oxygen saturation as measured by pulse oximetry.
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ciated with all-cause mortality in the multivariable ana-
lysis. Both restrictive and obstructive airway diseases have
been associated with increased mortality in previous stud-
ies [19,42], and both moderate to very severe COPD and
restrictive lung diseases involve reduced FEV1% predicted.
For the participants with an FEV1% predicted of <50%,
almost 90% had an FEV1/FVC% <70, suggesting that the
low oxygen saturation observed in this group was prob-
ably caused by COPD.
Male sex is associated with a shorter life expectancy
than female sex. More men are former smokers and they
tend to smoke more pack-years than women, which may
explain some of the differences in life expectancy. The
prevalence of CVD is higher in men. Similar findings
have been found in another study [42].
Contrary to our previous study, we did in the current
study not find that increased haemoglobin concentration
was significantly associated with low SpO2. Few partici-
pants had a high haemoglobin concentration, and this
value was missing in 11% of the participants. This might
explain the lack of association in this study.
In a recent study, Smith et al. [43] reported increased
mortality rates in hospitalized patients with an SpO2 <
96%. Increased mortality has also been found in emer-
gency care patients with a low SpO2 [8,9]. SpO2 may be
a good predictor of mortality in situations where spir-
ometry is not available and in populations with a higher
frequency of low SpO2, especially when used as part of a
risk-scoring system.
Strengths and weaknesses
This study was based on a single-point measurement of
SpO2. We have not checked the reproducibility, but we
know that the group with the lowest SpO2 (≤92%) in the
follow-up examinations also showed consistently low
values for SaO2 in blood gas analysis. Oxygen saturation
can vary during the day, especially during activity and at
night in people with a pulmonary disease such as COPD
[44]. Baseline SpO2 (at rest) has been shown to predict
oxygen desaturation during activity [3] and at night [4].
SpO2 can also be in the normal range even though FEV1%
predicted is <50%.
The measurement of SpO2 could be a limitation because
the accuracy of the device is ±2 digits. We tried to com-
pensate for this possible confounding factor by using the
highest of three measurements and categorizing the par-
ticipants into groups.
The group with SpO2 ≤ 92% in this population was small
and comprised only 1.0% of the entire population. One rea-
son may be that people with the lowest values were too sick
to participate. We might have found a stronger association
with SpO2 in groups of patients with diseases such as COPD
because such groups have a higher frequency of low SpO2.The participation rate was lower in the oldest age group
and in the youngest men. This might have affected our re-
sults by missing the sickest (oldest) and healthiest (youn-
gest) groups.
We did not measure post-bronchodilator spirometry. A
previous study has shown that this is probably not neces-
sary when mortality is evaluated in population studies [42].
Recall bias and misclassification errors are major con-
cerns when using questionnaires. A stronger association
between smoking and mortality may have been observed
if more valid data on pack-years had been obtained.
Measuring oxygen saturation by pulse oximetry has im-
portant limitations [45], especially when measuring values
at the lower levels. Saturation may be overestimated in
heavy smokers because high carboxyhaemoglobin levels
may cause overestimation of the true SpO2. To validate
the data for a particular device, future studies could in-
clude gas analysis in a subsample for comparison.
The cause of death may be uncertain or wrong in many
instances because only a small percentage has an autopsy
done (10–12% in Norway). Among the participants who
died during this study, 36.9% had an FEV1/FVC% <70,
and 9.2% reported having COPD. COPD as the main diag-
nosis or as one of the comorbidities was reported by only
6.5%.
Conclusions
We observed that lower values from pulse oximetry
were associated with increased all-cause mortality in the
general adult population. This was probably because of
the strong association with death caused by pulmonary
diseases. The association was weakened and no longer sta-
tistically significant after adjusting for FEV1% predicted
but remained significant for death caused by pulmonary
diseases. Pulse oximetry is easy and safe to perform, and
may be particularly useful in risk assessment when spir-
ometry is not an option and when added to spirometry for
assessing the risk of death because of pulmonary disease.
Low pulse oximetry values found in a patient should war-
rant further examination.
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